创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

杨建红, 张彦彦, 李长青, 姚佩颖, 陈江鹏, 吕心欢, 肖瑶, 张象麟. 关于完善我国伦理委员会管理制度的建议[J]. 药学进展, 2021, 45(9): 663-668.
引用本文: 杨建红, 张彦彦, 李长青, 姚佩颖, 陈江鹏, 吕心欢, 肖瑶, 张象麟. 关于完善我国伦理委员会管理制度的建议[J]. 药学进展, 2021, 45(9): 663-668.
YANG Jianhong, ZHANG Yanyan, LI Changqing, YAO Peiying, CHEN Jiangpeng, LYU Xinhuan, XIAO Yao, ZHANG Xianglin. Suggestions on Improving the Management System of China's Ethics Committee[J]. Progress in Pharmaceutical Sciences, 2021, 45(9): 663-668.
Citation: YANG Jianhong, ZHANG Yanyan, LI Changqing, YAO Peiying, CHEN Jiangpeng, LYU Xinhuan, XIAO Yao, ZHANG Xianglin. Suggestions on Improving the Management System of China's Ethics Committee[J]. Progress in Pharmaceutical Sciences, 2021, 45(9): 663-668.

关于完善我国伦理委员会管理制度的建议

Suggestions on Improving the Management System of China's Ethics Committee

  • 摘要: 通过对其他国家及地区伦理委员会管理制度的研究,基于我国伦理委员会管理制度的现状,结合专家研讨和问卷调研结果,最终围绕我国伦理委员会伦理审查质量、伦理委员会审查效率、首次伦理审查与临床审评的顺序、创新药的伦理审查和伦理委员会的监管等方面提出相关建议,为完善我国伦理委员会管理制度提供参考。

     

    Abstract: Based on the research on the management system of Ethics Committee in other countries and regions in the world, its current situation in China, and the results of interviews with experts and questionnaires, this paper puts forward some suggestions on the quality of ethical review in China, the efficiency of Ethics Committee review, beginning time for ethics review, the order of clinical review, ethical review of innovative drugs, and supervision of Ethics Committees, aiming to provide reference for perfecting the management system of Ethics Committee in China.

     

/

返回文章
返回